Diabetic retinopathy, a leading cause of blindness in working-age adults, silently damages eyes through high blood sugar.

The Heat led by 14 points in the second half, but still fell to the short-handed Cavaliers on Wednesday night.

Discover Q3 2025 earnings insights from CV Sciences, Inc. See how cost control, new products, and advocacy efforts drive growth amid regulatory change.

Early detection and proactive health management are crucial in cancer treatment, as highlighted by the patient's initial symptoms and subsequent monitoring. Lifestyle changes, including dietary ...

As the largest demographic of deer hunters ages and opts out, concerns grow about the ability to control Wisconsin's ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...

Produced Higher Margins, Lower Operating Expenses, and Significantly Narrowed Losses Compared to Q2 2025 New Product ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Tata Motors, which now represents the automaker's commercial vehicle business, on November 13 reported a consolidated net loss of Rs 867 crore for the second quarter of the financial year 2026. This ...

Third quarter revenue increased 98% from the previous quarter and increased 38% from the prior year quarter; Alpha team prepares to return to flight; SciTec acquisition closes Blue Ghost Mission 2 str ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...